Hepatitis C virus contributes to hepatocarcinogenesis by modulating metabolic and intracellular signaling pathways - PubMed

Review

Hepatitis C virus contributes to hepatocarcinogenesis by modulating metabolic and intracellular signaling pathways

Kazuhiko Koike. J Gastroenterol Hepatol. 2007 Jun.

Erratum in

• J Gastroenterol Hepatol. 2008 Mar;23(3):501-2

Abstract

Persistent infection with hepatitis C virus (HCV) is a major risk factor for development of hepatocellular carcinoma (HCC). However, it remains controversial in the pathogenesis of HCC associated with HCV as to whether the virus plays a direct or an indirect role. The studies using transgenic mouse models, in which the core protein of HCV has an oncogenic potential, indicate that HCV is directly involved in hepatocarcinogenesis, albeit other factors such as continued cell death and regeneration associated with inflammation would also play a role. The downstream events of the core protein are segregated into two components. One is the augmented production of oxidative stress along with the activation of scavenging system, including catalase and glutathione, in the putative pre-neoplastic stage with steatosis in the liver. Thus, oxidative stress production in the absence of inflammation by the core protein would partly contribute to the development of HCC. The generation of oxidative stress is estimated to originate from mitochondrial dysfunction in hepatocytes by HCV infection. The other component is the alteration of intracellular signaling cascade of mitogen-activated protein kinase and activating factor (AP)-1, leading to the activation of cell cycle control. The combination of these pathways, collective with HCV-associated alterations in lipid and glucose metabolism, would lead to the frequent development of HCC in persistent HCV infection. These results suggest that there would be a mechanism for hepatocarcinogenesis in persistent HCV infection that is distinct from those for the other cancers. Similar to the pathogenesis of other cancers, the accumulation of a set of genetic aberrations may also be necessary for a multistage development of HCC. However, HCV core protein, to which an oncogenic potential is ascribed, may allow some of the multiple steps to be bypassed in hepatocarcinogenesis. Therefore unlike for other cancers, HCV infection may be able to cause HCC in the absence of a complete set of genetic aberrations. Such a scenario, 'non-Vogelstein-type' carcinogenesis, would explain the rare feature of hepatocarcinogenesis in HCV infection, the extraordinarily high incidence and the multicentric nature of HCC development.

Similar articles

• [HCV core gene transgenic mouse as a model for viral hepatocarcinogenesis].

  Koike K. Koike K. Nihon Rinsho. 2001 Jul;59(7):1265-70. Nihon Rinsho. 2001. PMID: 11494535 Review. Japanese.

• Molecular basis for the synergy between alcohol and hepatitis C virus in hepatocarcinogenesis.

  Koike K, Tsutsumi T, Miyoshi H, Shinzawa S, Shintani Y, Fujie H, Yotsuyanagi H, Moriya K. Koike K, et al. J Gastroenterol Hepatol. 2008 Mar;23 Suppl 1:S87-91. doi: 10.1111/j.1440-1746.2007.05292.x. J Gastroenterol Hepatol. 2008. PMID: 18336672

• Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis.

  Moriya K, Nakagawa K, Santa T, Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Miyazawa T, Ishibashi K, Horie T, Imai K, Todoroki T, Kimura S, Koike K. Moriya K, et al. Cancer Res. 2001 Jun 1;61(11):4365-70. Cancer Res. 2001. PMID: 11389061

• Pathogenesis of HCV-associated HCC: Dual-pass carcinogenesis through activation of oxidative stress and intracellular signaling.

  Koike K. Koike K. Hepatol Res. 2007 Sep;37 Suppl 2:S115-20. doi: 10.1111/j.1872-034X.2007.00173.x. Hepatol Res. 2007. PMID: 17877471

• Viral hepatitis and liver cancer: the case of hepatitis C.

  Levrero M. Levrero M. Oncogene. 2006 Jun 26;25(27):3834-47. doi: 10.1038/sj.onc.1209562. Oncogene. 2006. PMID: 16799625 Review.

Cited by

• Viral hepatitis: HCV compartmentalization in HCC: driver, passenger or both?

  Holmes JA, Chung RT. Holmes JA, et al. Nat Rev Gastroenterol Hepatol. 2016 May;13(5):254-6. doi: 10.1038/nrgastro.2016.46. Epub 2016 Mar 23. Nat Rev Gastroenterol Hepatol. 2016. PMID: 27006254 No abstract available.

• Hepatitis C virus-induced hepatocellular carcinoma.

  Goossens N, Hoshida Y. Goossens N, et al. Clin Mol Hepatol. 2015 Jun;21(2):105-14. doi: 10.3350/cmh.2015.21.2.105. Epub 2015 Jun 26. Clin Mol Hepatol. 2015. PMID: 26157746 Free PMC article. Review.

• An Ecological Framework of the Human Virome Provides Classification of Current Knowledge and Identifies Areas of Forthcoming Discovery.

  Parker MT. Parker MT. Yale J Biol Med. 2016 Sep 30;89(3):339-351. eCollection 2016 Sep. Yale J Biol Med. 2016. PMID: 27698618 Free PMC article. Review.

• Microenvironment and tumor cells: two targets for new molecular therapies of hepatocellular carcinoma.

  Amicone L, Marchetti A. Amicone L, et al. Transl Gastroenterol Hepatol. 2018 May 2;3:24. doi: 10.21037/tgh.2018.04.05. eCollection 2018. Transl Gastroenterol Hepatol. 2018. PMID: 29971255 Free PMC article. Review.

• Hepatitis C virus NS2 protein inhibits DNA damage pathway by sequestering p53 to the cytoplasm.

  Bittar C, Shrivastava S, Bhanja Chowdhury J, Rahal P, Ray RB. Bittar C, et al. PLoS One. 2013 Apr 30;8(4):e62581. doi: 10.1371/journal.pone.0062581. Print 2013. PLoS One. 2013. PMID: 23638118 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Wiley

• Medical

  • MedlinePlus Health Information